1-(5-Methyl-1,2,4-oxadiazol-3-yl)ethan-1-amine hydrochloride | 1423031-33-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(5-Methyl-1,2,4-oxadiazol-3-yl)ethan-1-amine hydrochloride
• 英文别名: 1-(5-methyl-1,2,4-oxadiazol-3-yl)ethanamine;hydrochloride
• CAS: 1423031-33-7
• 化学式: C5H10ClN3O
• mdl: MFCD16990592
• 分子量: 163.6
• InChiKey: YRFQYNOIIKXUJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.13
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN<br/>[FR] ANTAGONISTES DU RÉCEPTEUR P2X3 UTILISÉS DANS LE TRAITEMENT DE LA DOULEUR
  申请人：MERCK & CO INC

  公开号：WO2009058298A1

  公开（公告）日：2009-05-07

  The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

  本发明涉及新颖的P2X3受体拮抗剂，这些拮抗剂在治疗与疼痛相关的疾病状态中发挥关键作用，特别是可以使用P2X3受体亚单位调节剂来治疗的外周疼痛、炎症性疼痛或组织损伤疼痛。
• 2-quinolone derived inhibitors of BCL6
  申请人：Cancer Research Technology Limited

  公开号：US11161839B2

  公开（公告）日：2021-11-02

  The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

  本发明涉及作为 BCL6（B 细胞淋巴瘤 6）活性抑制剂的式 I 化合物： 式 I 其中 X1、X2、X3、R1、R2、R3、R4 和 R5 各如本文所定义。 本发明还涉及这些化合物的制备工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 BCL6 活性的疾病或病症中的用途。
• P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2215049A1

  公开（公告）日：2010-08-11
• 2-QUINOLONE DERIVED INHIBITORS OF BCL6
  申请人：Cancer Research Technology Limited

  公开号：US20210206756A1

  公开（公告）日：2021-07-08

  The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 4 and R 5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
• AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20220227749A1

  公开（公告）日：2022-07-21

  The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X 3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).